IN2014MN01486A - - Google Patents
Info
- Publication number
- IN2014MN01486A IN2014MN01486A IN1486MUN2014A IN2014MN01486A IN 2014MN01486 A IN2014MN01486 A IN 2014MN01486A IN 1486MUN2014 A IN1486MUN2014 A IN 1486MUN2014A IN 2014MN01486 A IN2014MN01486 A IN 2014MN01486A
- Authority
- IN
- India
- Prior art keywords
- hcv
- inhibitors
- solvates
- meaning
- preparing
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11195841 | 2011-12-28 | ||
| EP12152267 | 2012-01-24 | ||
| PCT/EP2012/076942 WO2013098320A1 (en) | 2011-12-28 | 2012-12-27 | Quinazolinone derivatives as hcv inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01486A true IN2014MN01486A (OSRAM) | 2015-04-24 |
Family
ID=47505013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1486MUN2014 IN2014MN01486A (OSRAM) | 2011-12-28 | 2012-12-27 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9382261B2 (OSRAM) |
| EP (1) | EP2797913B1 (OSRAM) |
| JP (2) | JP6199891B2 (OSRAM) |
| CN (1) | CN104169271B (OSRAM) |
| AU (1) | AU2012360910B8 (OSRAM) |
| BR (1) | BR112014016007A8 (OSRAM) |
| CA (1) | CA2858646A1 (OSRAM) |
| ES (1) | ES2601461T3 (OSRAM) |
| IN (1) | IN2014MN01486A (OSRAM) |
| MX (1) | MX348127B (OSRAM) |
| RU (1) | RU2014131017A (OSRAM) |
| WO (1) | WO2013098320A1 (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| CN105530933B (zh) | 2013-07-17 | 2018-12-11 | 百时美施贵宝公司 | 用于治疗hcv的包含联苯衍生物的组合产品 |
| US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8143288B2 (en) | 2005-06-06 | 2012-03-27 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7659270B2 (en) * | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EA200970375A1 (ru) | 2006-10-13 | 2009-10-30 | Президио Фармасьютикалз, Инк. | Соединения и способы лечения вируса гепатита с |
| US20100055071A1 (en) | 2006-11-21 | 2010-03-04 | Martin Robert Leivers | Anti-Viral Compounds |
| US7906655B2 (en) | 2008-08-07 | 2011-03-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| SG171890A1 (en) | 2008-12-03 | 2011-07-28 | Presidio Pharmaceuticals Inc | Inhibitors of hcv ns5a |
| HK1203929A1 (en) * | 2008-12-03 | 2015-11-06 | 普雷西迪奥制药公司 | Inhibitors of hcv ns5a |
| WO2011004276A1 (en) * | 2009-07-06 | 2011-01-13 | Pfizer Limited | Hepatitis c virus inhibitors |
| UA108211C2 (uk) | 2009-11-04 | 2015-04-10 | Янссен Рід Айрленд | Бензімідазолімідазольні похідні |
| WO2011091446A1 (en) * | 2010-01-22 | 2011-07-28 | Glaxosmithkline Llc | Chemical compounds |
| KR20120124495A (ko) * | 2010-03-04 | 2012-11-13 | 이난타 파마슈티칼스, 인코포레이티드 | Ｈｃｖ 복제의 억제제로서의 조합 제약 작용제 |
| AU2011284857B2 (en) | 2010-07-26 | 2014-07-24 | Janssen Sciences Ireland Uc | Hetero-bicyclic derivatives as HCV inhibitors |
| ES2558608T3 (es) * | 2011-12-28 | 2016-02-05 | Janssen Sciences Ireland Uc | Derivados hetero-bicíclicos como inhibidores del VHC |
-
2012
- 2012-12-27 AU AU2012360910A patent/AU2012360910B8/en not_active Ceased
- 2012-12-27 US US14/368,511 patent/US9382261B2/en not_active Expired - Fee Related
- 2012-12-27 ES ES12810312.4T patent/ES2601461T3/es active Active
- 2012-12-27 CA CA2858646A patent/CA2858646A1/en not_active Abandoned
- 2012-12-27 EP EP12810312.4A patent/EP2797913B1/en not_active Not-in-force
- 2012-12-27 CN CN201280065174.5A patent/CN104169271B/zh not_active Expired - Fee Related
- 2012-12-27 MX MX2014008042A patent/MX348127B/es active IP Right Grant
- 2012-12-27 JP JP2014549464A patent/JP6199891B2/ja not_active Expired - Fee Related
- 2012-12-27 RU RU2014131017A patent/RU2014131017A/ru not_active Application Discontinuation
- 2012-12-27 BR BR112014016007A patent/BR112014016007A8/pt not_active IP Right Cessation
- 2012-12-27 WO PCT/EP2012/076942 patent/WO2013098320A1/en active Application Filing
- 2012-12-27 IN IN1486MUN2014 patent/IN2014MN01486A/en unknown
-
2017
- 2017-07-28 JP JP2017146186A patent/JP2018012699A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP6199891B2 (ja) | 2017-09-20 |
| US20140378485A1 (en) | 2014-12-25 |
| WO2013098320A1 (en) | 2013-07-04 |
| JP2018012699A (ja) | 2018-01-25 |
| MX2014008042A (es) | 2014-08-21 |
| CN104169271B (zh) | 2017-04-05 |
| RU2014131017A (ru) | 2016-02-20 |
| CN104169271A (zh) | 2014-11-26 |
| BR112014016007A8 (pt) | 2017-07-04 |
| ES2601461T3 (es) | 2017-02-15 |
| AU2012360910A8 (en) | 2017-02-02 |
| US9382261B2 (en) | 2016-07-05 |
| MX348127B (es) | 2017-05-26 |
| BR112014016007A2 (pt) | 2017-06-13 |
| AU2012360910B2 (en) | 2017-01-05 |
| AU2012360910A1 (en) | 2014-06-26 |
| EP2797913A1 (en) | 2014-11-05 |
| EP2797913B1 (en) | 2016-08-17 |
| CA2858646A1 (en) | 2013-07-04 |
| JP2015503537A (ja) | 2015-02-02 |
| AU2012360910B8 (en) | 2017-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019502355A1 (en) | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b | |
| PH12018501812A1 (en) | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
| MX2015011229A (es) | Sulfamoil-arilamidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis b. | |
| PH12016500027A1 (en) | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
| PH12016500723B1 (en) | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
| PH12015500780A1 (en) | Rsv antiviral compounds | |
| MX366787B (es) | Derivados de sulfamoiltiofenamida y su uso como medicamentos para tratar la hepatitis b. | |
| IN2014MN01465A (OSRAM) | ||
| MX2015014033A (es) | Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. | |
| UA115069C2 (uk) | Конденсовані біциклічні похідні сульфамоїлу та їх застосування як лікарських препаратів для лікування гепатиту b | |
| JO3115B1 (ar) | مركبات بيريدازينون واستخدامها كمثبطات daao | |
| EA201390163A1 (ru) | Гетеробициклические производные в качетстве ингибиторов hcv | |
| IN2014MN01486A (OSRAM) | ||
| TN2013000150A1 (en) | Co-crystals and salts of ccr3-inhibitors | |
| TN2014000077A1 (en) | Pyridazinone compounds and their use as daao inhibitors |